Close Menu

Fluidigm

The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

Fluidigm will develop a microfluidic device for single-cell measurement of epigenetic changes under a broader $27.8 million DARPA-funded project.

The method combines DNA-barcoded antibodies with signal amplification for multiplexed protein imaging at subcellular resolution and relatively high throughput.

Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.

Year-over-year revenues increased on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.

The index, which underperformed the Dow Jones and the Nasdaq, fell nearly 3 percent in April.

The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.

Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.